Home » Topics » Regulatory » NMPA

NMPA
RSS

Linzess approved in China for IBS with constipation

Jan. 16, 2019

Chinese NMPA accepts IND for Asceltis Pharma's third HCV drug ASC-21

Jan. 3, 2019

Tyvyt approved in China for the treatment of Hodgkin's lymphoma

Dec. 27, 2018

Toripalimab first domestically produced anti-PD-1 MAb approved in China

Dec. 20, 2018

China becomes first country to approve roxadustat

Dec. 18, 2018

China SFDA clears phase I trial of A-319 in B-cell malignancies

Nov. 13, 2018

Elunate approved in China for colorectal cancer

Sep. 5, 2018

CFDA approves INDs for Innovent's IBI-101 and IBI-307

July 27, 2018

Luye cleared for phase I trials in China with LY-03012

June 21, 2018

CFDA grants priority review to Pharnext's PXT-3003 for CMT1A

June 14, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...